Principal Investigator
Jonathan Trent
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240908
Clinical Trial Summary
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose
Escalation and Expansion Study to Evaluate the Safety,
Pharmacokinetics, and Antitumor activity of ADCE-D01, a
Humanized Anti-human uPARAP Antibody Linked to a
Topoisomerase I Inhibitor, in Patients with Metastatic and/or
Unresectable Soft Tissue Sarcoma
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Bone and Soft Tissue Cancers
Contact Information
Phone Number
+1 (954) 8177628